By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


Key Statistics

Ownership: Public

Web Site: Bristol-Myers Squibb
Symbol: BMY



PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech  - Cancer

Gilead (Seattle, WA) 

Company News
Ariad (ARIA) Names Former Bristol-Myers Squibb (BMY) Exec as Chief Commercial Officer 5/25/2016 6:11:52 AM
Bristol-Myers Squibb (BMY) Release: Two-Year Overall Survival Data From Two Pivotal Opdivo (Nivolumab) Trials Demonstrate Sustained Benefit In Patients With Advanced Non-Small Cell Lung Cancer 5/19/2016 11:35:28 AM
Inovalon Announces Agreement With Bristol-Myers Squibb (BMY) To Focus On Real World Outcomes & Value-Based Contracting Initiatives 5/19/2016 8:48:53 AM
Bristol-Myers Squibb (BMY) Release: Opdivo (nivolumab) Granted First Approval Of A PD-1 Inhibitor In Hematology For The Treatment Of Classical Hodgkin Lymphoma Patients Who Have Relapsed Or Progressed After Auto-HSCT And Post-Transplantation Brentuximab Vedotin By The FDA 5/18/2016 10:56:29 AM
Breadth And Depth Of Bristol-Myers Squibb (BMY)’s Immuno-Oncology Clinical Development Program To Be Showcased At 2016 ASCO Annual Meeting 5/18/2016 9:07:49 AM
Bristol-Myers Squibb (BMY)'s $280 Million Massachusetts Expansion to Create Up to 350 New Jobs 5/17/2016 11:37:32 AM
Bristol-Myers Squibb (BMY) And AbbVie (ABBV) Announce European Commission Approval Of Empliciti (Elotuzumab) For The Treatment Of Multiple Myeloma In Adult Patients Who Have Received At Least One Prior Therapy 5/12/2016 11:16:38 AM
European Commission (EC) Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) + Yervoy (Ipilimumab) Regimen, for Treatment of Advanced Melanoma 5/11/2016 10:53:05 AM
Allied Minds and Bristol-Myers Squibb (BMY) Throw Another $100 Million into the Development of 10 Drugs 4/29/2016 6:16:26 AM
Bristol-Myers Squibb (BMY) Reports First Quarter Financial Results 4/28/2016 11:01:35 AM